InvAscent
Henal Agrawal currently serves as the Director at InvAscent since February 2025. Prior to this role, Henal was the Vice President of Private Equity at Tata Capital, contributing to notable investments in Orbicular Pharmaceutical Technologies and Sakar Healthcare. With previous experience as Chief Manager in M&A at Piramal Enterprises and Associate Vice President at KPMG, Henal has a strong background in pharmaceuticals, chemicals, and related sectors, providing advisory services for high-profile acquisitions and divestments. Earlier roles included positions at Merisis Advisors and Devenio Optimus Advisors focusing on investment banking, and corporate banking at ICICI Bank. Henal's academic credentials include a BTech in Computer Science from the Indian Institute of Technology, Kharagpur, and an MBA in Finance from the Indian Institute of Management, Indore.
This person is not in any teams
This person is not in any offices
InvAscent
InvAscent is the investment advisor to EILSF (Fund I), India Life Sciences Fund II (ILSF-II) and India Life Sciences Fund III (ILSF-III). These funds provide private equity growth capital to companies in the Indian pharmaceutical, healthcare, animal health and medtech industries. Examples of funds usage include capacity expansion, introduction of new products, acquisitions, etc. The typical investment size is in the range of USD 10 - 40 million over the life of the investment for a significant minority stake. Fund-I made 8 investments during the period 2007-12 and has exited all 8 investments. ILSF-II is partially exited with 12 investments and 8 exits. ILSF-III is fully invested with 13 investments.